MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: GlobeNewswire
Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023YTD 2024 Total revenues of $209M; +49% vs. YTD 2023YTD 2024 Net income of $20 million; Non-GAAP net income of $45 millionOrphan lung disease studies proceeding as planned MNKD-101 Phase 3 clinical trial expands globallyMNKD-201 Phase 1 successfully completed; Plan to meet with FDA in 1H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended September 30, 2024. “Our business demonstrated double-digit revenue growth compared to last year, led by Tyvaso DPI revenues,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “The third quarter has also been marked by strong progress in our clinical development programs, with enrollment underway in the Phase 3 trial of MNKD-101 to study its effect in NTM lung disease and successful complet
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22 [Yahoo! Finance]Yahoo! Finance
- MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22GlobeNewswire
- MannKind Co. (NASDAQ: MNKD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- MannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now [Yahoo! Finance]Yahoo! Finance
- MannKind Co. (NASDAQ: MNKD) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.MarketBeat
MNKD
Earnings
- 2/26/25 - Beat
MNKD
Sec Filings
- 2/26/25 - Form S-3ASR
- 2/26/25 - Form 10-K
- 2/26/25 - Form 8-K
- MNKD's page on the SEC website